Filter News
Area of Research
- (-) Neutron Science (4)
- (-) Nuclear Science and Technology (1)
- Advanced Manufacturing (1)
- Biology and Environment (5)
- Clean Energy (32)
- Computational Biology (1)
- Computational Engineering (1)
- Computer Science (1)
- Electricity and Smart Grid (1)
- Fusion and Fission (1)
- Isotopes (4)
- Materials (7)
- Materials for Computing (1)
- National Security (2)
- Sensors and Controls (2)
- Supercomputing (3)
News Type
News Topics
- (-) Biomedical (4)
- (-) Space Exploration (1)
- 3-D Printing/Advanced Manufacturing (2)
- Advanced Reactors (1)
- Artificial Intelligence (2)
- Bioenergy (1)
- Biology (2)
- Chemical Sciences (1)
- Composites (1)
- Computer Science (5)
- Coronavirus (2)
- Fusion (1)
- High-Performance Computing (1)
- Isotopes (2)
- Materials (3)
- Materials Science (6)
- Microscopy (1)
- Molten Salt (3)
- Nanotechnology (3)
- Neutron Science (18)
- Nuclear Energy (5)
- Physics (2)
- Quantum Computing (1)
- Quantum Science (2)
- Transportation (2)
Media Contacts
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
Researchers from NASA’s Jet Propulsion Laboratory and Oak Ridge National Laboratory successfully created amorphous ice, similar to ice in interstellar space and on icy worlds in our solar system. They documented that its disordered atomic behavior is unlike any ice on Earth.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.
A team of scientists, led by University of Guelph professor John Dutcher, are using neutrons at ORNL’s Spallation Neutron Source to unlock the secrets of natural nanoparticles that could be used to improve medicines.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.